

HOUSE No. 2097

By Ms. Fox of Boston, petition of Gloria L. Fox and others for legislation to establish a high containment biological research laboratory health and safety program by the Department of Public Health. Public Health.

The Commonwealth of Massachusetts

PETITION OF:

| | |
|-------------------------|------------------------|
| Gloria L. Fox | Anthony J. Verga |
| Jarrett T. Barrios | Matthew C. Patrick |
| Byron Rushing | Peter V. Kocot |
| Willie Mae Allen | Steven J. D'Amico |
| Benjamin Swan | Alice K. Wolf |
| William Lantigua | Douglas W. Petersen |
| Elizabeth A. Malia | Patricia D. Jehlen |
| William N. Brownsberger | Dianne Wilkerson |
| Linda Dorcena Forry | J. James Marzilli, Jr. |
| Denise Provost | Carl M. Sciortino, Jr. |
| Timothy J. Toomey, Jr. | Martha M. Walz |
| Barbara A. L'Italien | Jennifer M. Callahan |

In the Year Two Thousand and Seven.

AN ACT PROMOTING RESEARCH AND PROTECTING PUBLIC SAFETY AND ENVIRONMENT.

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:

1 SECTION 1. Chapter 17 of the General Laws, as appearing in the
2 2004 official edition is hereby amended by inserting after Section 17
3 the following:- Section 18. Biological Agents Registry Program (a)
4 Definitions. As used in this section the following words shall have
5 the following meanings:—
6 “Biological agent,” any microorganism (including bacteria, virus,
7 fungus, and protozoa), or infectious substance, or any naturally
8 occurring, bioengineered, or synthesized component of any such
9 microorganism or infectious substance, capable of causing: death,
10 disease, or other biological malfunction in a human, an animal, a
11 plant, or another living organism; deterioration of food, water,

12 equipment, supplies, or material of any kind; or deleterious alter-
13 ation of the environment.

14 “Department,” the Department of Public Health.

15 “Person,” any state, public, or private corporation or authority,
16 any individual, trust, firm, joint stock company, partnership, associa-
17 tion, or other entity, or any group thereof, and any officer, employee,
18 or agent of such person, any group of persons, and any agency or
19 political subdivision of the Commonwealth or of the federal govern-
20 ment.

21 “Program,” the Biological Agents Registry Program.

22 “Select Agents and Toxins” a biological agent or toxin as defined
23 in Title 42, Part 73 of the Code of Federal Regulations, Title 9, Part
24 121 of the Code of Federal Regulations, or Title 7, Part 331 of the
25 Code of Federal Regulations.

26 “Toxin,” any toxic material or product of plants, animals,
27 microorganisms (including bacteria, virus, fungus, rickettsiae, or
28 protozoa), or infectious substance, or a recombinant or synthesized
29 molecule, whatever their origin and method of production, and
30 includes: any poisonous substance or biological product that may be
31 engineered as a result of biotechnology produced by a living
32 organism; or any poisonous isomer or biological product, homolog,
33 or derivative of such a substance.

34 (b) There is established in the department a Biological Agents
35 Registry Program.

36 (c) The Biological Agents Registry shall:—

37 (1) Identify the select agents and toxins, and other biological
38 agents and toxins, as determined by the department, possessed and
39 maintained by any person in the Commonwealth; and

40 (2) Contain other information as required by regulations of the
41 department.

42 (d) The department shall adopt regulations for the implementation
43 of the program that:—

44 (1) Determine and list the biological agents and toxins required to
45 be reported under this section, which shall include:—

46 i. All select agents and toxins, provided that the department may
47 exempt select agents and toxins that Title 42, Part 72 or 73 of the
48 Code of Federal Regulations, Title 9, Part 121 of the Code of Fed-
49 eral Regulation, or Title 7, Part 331 of the Code of Federal Regula-
50 tions exempt from their provisions; and

51 ii. Other biological agents and toxins as determined by the depart-
52 ment.

53 (2) Designate the persons required to make reports and the spe-
54 cific information required to be reported;

55 (3) Designate time limits for reporting, the form of reports, and
56 the persons to whom reports are to be submitted;

57 (4) Require local boards of health to be informed of the location
58 and nature of the biological agents and toxins in the registry that are
59 located within the local jurisdiction;

60 (5) Provide for the release of information in the Biological Agents
61 Registry to:—

62 i. Municipal, state and federal law enforcement agencies and the
63 Centers for Disease Control and Prevention pursuant to a communi-
64 cable disease or laboratory-acquired infection investigation com-
65 menced or conducted by the department or municipal, state, or
66 federal law enforcement agency having investigatory authority, or in
67 connection with any investigation involving a release, spread, theft,
68 illicit sale, or loss of biological agents;

69 ii. The Massachusetts emergency management agency and the
70 Massachusetts department of the environmental protection for the
71 purposes of planning for the protection of the public in relation to
72 the release of a biological agent and the prevention of a release of a
73 biological agent; and

74 iii. The Massachusetts emergency medical services system for the
75 purposes of providing certain specified information to:—

76 (A) A police officer or firefighter responding to an emergency;
77 and

78 (B) An emergency medical services provider performing emer-
79 gency services responding to a fire or other emergency, or dis-
80 patched on a call for emergency services;

81 (6) Establish a process for persons that possess and maintain
82 select agents and toxins and other biological agents and toxins to
83 alert appropriate authorities of unauthorized possession or attempted
84 possession of such biological agents or toxins

85 (e) A person that possesses and maintains biological agents and
86 toxins shall report to the department the information required by the
87 department for inclusion in the Biological Agents Registry unless
88 the department determines that the select agents and toxins, certified
89 laboratory, or facility is exempt from the requirements for the inter-

90 state shipment of etiologic agents under Title 42, Part 72.6(h) or Part
91 72, Appendix A of the Code of Federal Regulations.

92 (f) Information prepared for or maintained in the Biological
93 Agents Registry shall be subject to Chapter 66 of the General Laws,
94 provided that information released from the Registry is not conse-
95 quently a public record and a person to whom information has been
96 released from the Registry may not release the information unless
97 such release is approved by the department.

98 (g) A person who violates a provision of this section is guilty of a
99 misdemeanor and on conviction is subject to a fine not exceeding
100 \$1000 for the first offense and not exceeding \$5000 for each subse-
101 quent conviction for a violation of the same provision. Each day a
102 violation is continued after the first conviction is a subsequent
103 offense.

104 Section 19. High Containment Biological Research Laboratory
105 Health and Safety Program.

106 (a) Definitions. As used in this section the following words shall
107 have the following meanings:—

108 “Biological agent,” any microorganism (including bacteria, virus,
109 fungus, and protozoa), or infectious substance, or any naturally
110 occurring, bioengineered, or synthesized component of any such
111 microorganism or infectious substance, capable of causing: death,
112 disease, or other biological malfunction in a human, an animal, a
113 plant, or another living organism; deterioration of food, water, equip-
114 ment, supplies, or material of any kind; or deleterious alteration of
115 the environment.

116 “Biosafety in Microbiological and Biomedical Laboratories” or
117 “BMBL,” a publication that lists the standards and special microbio-
118 logical practices, safety equipment and facilities constituting
119 Biosafety Levels 1-4, most recent edition, published by the United
120 States Department of Health and Human Services, Public Health
121 Service, the Centers for Disease Control and Prevention and the
122 National Institutes of Health. If the publication is discontinued, the
123 most recent edition shall remain in effect as thereafter modified from
124 time to time by regulation of the department.

125 “Biosafety Level 3 laboratory” or “BSL3 laboratory,” a laboratory
126 that is designed, equipped, or operated as a Biosafety level 3 labora-
127 tory as defined by the United States National Institutes of Health

128 Guidelines for Research Involving Recombinant DNA Molecules
129 (NIH Guidelines).

130 “Biosafety Level 4 laboratory” or “BSL4 laboratory,” a laboratory
131 that is designed, equipped, or operated as a biosafety level 4 labora-
132 tory as defined by the United States National Institutes of Health
133 Guidelines for Research Involving Recombinant DNA Molecules
134 (NIH Guidelines). “Department,” the Department of Public Health.

135 “Facility,” a building or combination of buildings under common
136 control and ownership containing one or more laboratories subject to
137 a common Institutional Biosafety Committee.

138 “High Containment Biological Research Laboratory,” a BSL3 or
139 BSL4 laboratory.

140 “Laboratory,” a room or rooms that are used primarily for biolog-
141 ical research, development, non-routine testing, or experimentation
142 activity, or any room or rooms where vertebrate animals are con-
143 tained under animal biosafety levels three and four as described in
144 NIH Guidelines/BMBL Section IV. The word “laboratory” shall also
145 include those rooms that directly serve a laboratory and are within
146 the containment area.

147 “National Institutes of Health Guidelines” or “NIH Guidelines,”
148 the National Institutes of Health Guidelines for Research Involving
149 Recombinant Molecules, as amended from time to time. If the
150 National Institutes of Health shall discontinue or abolish said guide-
151 lines, the most recent guidelines shall remain in effect as thereafter
152 modified from time to time by regulation by the department.

153 “Person,” any state, public, or private corporation or authority,
154 any individual, trust, firm, joint stock company, partnership, associa-
155 tion, or other entity, or any group thereof, and any officer, employee,
156 or agent of such person, any group of persons, and any agency or
157 political subdivision of the Commonwealth or of the federal govern-
158 ment.

159 “Program,” the High Containment Biological Research Labora-
160 tory Health and Safety Program.

161 “Select Agents and Toxins,” a biological agent or toxin as defined
162 in Title 42, Part 73 of the Code of Federal Regulations, Title 9, Part
163 121 of the Code of Federal Regulations, or Title 7, Part 331 of the
164 Code of Federal Regulations.

165 “Toxin,” any toxic material or product of plants, animals,
166 microorganisms (including bacteria, virus, fungus, rickettsiae, or

167 protozoa), or infectious substance, or a recombinant or synthesized
168 molecule, whatever their origin and method of production, and
169 includes: any poisonous substance or biological product that may be
170 engineered as a result of biotechnology produced by a living
171 organism; or any poisonous isomer or biological product, homolog,
172 or derivative of such a substance.

173 (b) There is established in the department a High Containment
174 Biological Research Laboratory Health and Safety Program.

175 (c) The program shall provide standards for the location, opera-
176 tion, and maintenance of high containment biological research labo-
177 ratories and the oversight of such laboratories to protect the safety of
178 laboratory workers, the public, and the environment from select
179 agents and toxins.

180 (d) The department shall adopt regulations for the implementation
181 of the program that:—

182 (1) Set criteria for determining appropriate locations for siting a
183 building with a BSL4 laboratory, including whether a BSL4 labora-
184 tory may be created within an existing building, that at a minimum
185 include that:—

186 i. Sites shall not be within a floodplain, near a property whose
187 regular use could significantly endanger the site through fire or
188 explosion, or near an area of high traffic congestion that might
189 impede emergency access or evacuation or endanger motorists;

190 ii. Sites shall have sufficient land available to provide for a rea-
191 sonable buffer around the building, a minimum of 150 unobstructed
192 feet in every direction;

193 iii. Other criteria for consideration include: the proximity of flood
194 plains, wetlands, waterways, and water bodies; the relationship of
195 the site to groundwater elevations; the nature and extent of residen-
196 tial areas and schools through grade twelve in proximity to the site;
197 the availability and suitability of access roads to the site, including
198 the ability of first responders to access the site in an emergency; the
199 potential for adverse public health and safety impacts; the potential
200 impact of increased traffic volume on roads to the site; and the
201 potential threat of a terrorist attack on or infiltration of the building.

202 (2) Provide a process to determine whether to approve the siting
203 of a new BSL4 laboratory that includes:—

- 204 i. An application to be completed by a person wishing to site a
205 building with a BSL4 laboratory or add a BSL4 laboratory to an
206 existing building that did not have a BSL4 laboratory;
- 207 ii. The department holding a public hearing on the application in
208 the municipality where the laboratory would be located;
- 209 iii. The department, the department of environmental protection,
210 the board of health of the municipality in which the facility would be
211 located reviewing the application and approving the siting if they
212 determine that the proposed site and building would not constitute a
213 threat to the public health or safety or the environment;
- 214 iv. The decision on the siting is made in writing with findings as
215 to why the decision was made;
- 216 v. The approval or denial of siting may be appealed pursuant to
217 provisions of Section fourteen of Chapter thirty A;
- 218 (3) Require each facility with a BSL4 laboratory that has been
219 approved as required by subsection (2) to submit to the department
220 the construction plans for the facility, construction schedule, the
221 application submitted to the National Institutes of Health (NIH), if
222 applicable, the as-built plans when completed, and documentation of
223 third-party commissioning of the facility.
- 224 (4) Assure that high containment biological research laboratories
225 meet or exceed federal guidelines for health and safety practices,
226 including that:—
- 227 i. Each facility with a high containment biological research labo-
228 ratory complies with the most current versions of the following
229 guidelines:—
- 230 NIH Guidelines; BMBL; and Guidelines on Primary Containment
231 for Biohazards (Centers for Disease Control/NIH); or more protec-
232 tive regulations that the department might adopt.
- 233 ii. Each facility with a high containment biological research labo-
234 ratory shall establish an Institutional Biosafety Committee (IBC) in
235 accordance with the NIH Guidelines, whether it is NIH funded or
236 not. At least two members of the IBC shall be residents of the
237 municipality in which the facility is located and shall be independent
238 of the facility, its contractors, and consultants. One such member
239 shall be appointed by the department and the other shall be
240 appointed by the local board of health. A member appointed by the
241 department or local board of health may be rejected by the facility
242 only for good cause.

243 iii. An IBC shall comply with NIH Guidelines applicable to IBCs
244 for all research in high containment biological research laboratories,
245 whether recombinant DNA research or not, and may be further regu-
246 lated by the department. Each IBC for a facility with high contain-
247 ment biological research laboratory shall, at a minimum:—

248 (A) Provide the department with a complete list of all members of
249 the IBC, including member's name, title, business mailing address,
250 phone number, fax number, e-mail, and curriculum vitae. The list
251 and curriculum vitae shall be updated with any changes at least
252 annually.

253 (B) Review and approve all projects in facilities operating a high
254 containment biological research laboratory prior to the projects com-
255 mencing. A protocol registration document, as defined by the NIH
256 guidelines, shall be required for all approved IBC projects with
257 select agents and toxins and other regulated agents requiring BSL3
258 or BSL4 containment. The documents shall be sent to the depart-
259 ment and are subject to Chapter 66 of the General Laws.

260 (C) Take and keep minutes of IBC meetings that conform to the
261 NIH Guidelines and provide the minutes to the department. The
262 minutes shall be accessible for members who do not attend the meet-
263 ings. The minutes shall include, but not be limited to: IBC members
264 present at the meeting; a description of any current or pending
265 research; any comments or concerns made at the meeting; and any
266 voting, administrative matters, accident reporting or compliance
267 issues discussed. The department may provide the minutes to the
268 local board of health upon request.

269 (D) Inspect the high containment biological research laboratories
270 at least annually and submit the results of the inspections to the
271 department.

272 (E) Meet at least annually with a representative of the department
273 to review safety procedures, discuss health issues relating to opera-
274 tion of its facility, and such other issues identified by the department.

275 (F) Hold at least one public meeting annually to a report on health
276 and safety issues at the facility and take public comments about the
277 facility.

278 (5) Require prior approval by the department for research that
279 may or is intended to:—

280 i. Enhance the harmful consequences of a biological agent or
281 toxin. Harmful consequences include the ability to critically alter

282 normal biological functions, or inflict damage on public health
283 resources, materiel, and public safety. Enhancement includes aug-
284 menting properties such as virulence, infectivity, stability, transmis-
285 sibility, or the ability of the biological agent or toxin to be
286 disseminated;

287 ii. Disrupt immunity or the effectiveness of an immunization;

288 iii. Confer to a pathogenic agent or toxin resistance to clinically or
289 agriculturally useful prophylaxes or therapeutics against that agent
290 or toxin;

291 iv. Facilitate the ability of a biological agent or toxin to evade
292 detection methodologies;

293 v. Increase the stability, transmissibility, or the ability to dissemi-
294 nate a biological agent or toxin;

295 vi. Alter the host range or tropism of a pathogenic agent or toxin;

296 vii. Enhance the susceptibility of a host population, including by
297 immuno-modulation of the host to increase pathogenicity; or

298 viii. Generate a novel pathogenic agent or toxin or reconstitute an
299 eradicated or extinct pathogenic agent. A novel agent is an agent that
300 has not existed previously and is considered unique based on biolog-
301 ical or other properties and traits. Such approval may be granted
302 only upon a showing that the facility has taken special precautions to
303 minimize or eliminate health and safety risks arising from such
304 research.

305 (6) Require each facility with a high containment biological
306 research laboratory to complete a permit application and obtain a
307 permit from the department to operate its high containment biolog-
308 ical research laboratories. Said permits shall contain the terms and
309 conditions the department determines are necessary to protect
310 worker and public health and safety and the environment. Said per-
311 mits shall not exceed five years in duration but may be renewed or
312 reissued by the department after receipt of a new completed permit
313 application that meets regulatory requirements. The department may
314 issue or renew a permit only upon finding that no condition or cir-
315 cumstance exists in the facility that is prejudicial to worker or public
316 health and safety or the environment. The department may suspend
317 or revoke a permit upon finding that a condition or circumstance
318 exists in the facility that is prejudicial to worker or public health and
319 safety or the environment.

320 (7) Require each facility with a high containment biological
321 research laboratory to have a medical surveillance plan created in
322 consultation with a licensed physician experienced in occupational
323 health or infection control and familiar with biological laboratory
324 exposures and informed about select agents and toxins. The purpose
325 of the plan is to establish employee and researcher occupational
326 health records, document and require inoculation for diseases when a
327 safe vaccine is available, screen for illness among laboratory
328 workers, require reporting of laboratory accidents, monitor and track
329 releases and laboratory-acquired infections and spreads, and report
330 within the facility and to appropriate government entities. The
331 specifics of the medical surveillance and infection control protocol
332 must meet standards established by the department and be approved
333 by the department. The medical surveillance plan shall be imple-
334 mented through an employee experienced in occupational health or
335 infection control, familiar with biological laboratory exposures, and
336 informed about select agents and toxins. The employee shall also:—
337 i. Report any accidental or intentional human exposure to a patho-
338 genic biological agent or toxin, or reasonable likelihood of such
339 exposure, to the department as soon as possible and in no case more
340 than 24 hours after learning of the exposure;
341 ii. Report any accidental or intentional release or spread of a path-
342 ogenic biological agent or toxin, or reasonable likelihood of a
343 release or spread, outside the containment area of a BSL 3 or BSL4
344 laboratory to the department as soon as possible, and in no case
345 more than 24 hours after the release. The report also shall be pro-
346 vided to the board of health in the municipality in which the facility
347 is located and any other municipality affected by the release.
348 iii. Provide the IBC with a report of all incidents, accidents, and
349 other events that caused or are suspected to have caused a threat to
350 the public health, death, illness, or bodily injury to any person in the
351 laboratory, as they occur, but no later than 3 days after the incident.
352 (8) Require each facility with a high containment biological
353 research laboratory to have and implement a plan to provide ade-
354 quate training for the proper handling of pathogenic biological
355 agents and toxins that might be present in the laboratory. Such
356 training shall include, but not be limited to, decontamination
357 methods, personnel safety precautions and work habits, early
358 warning disease surveillance, and accident response actions and

359 notifications. The facility shall provide a training plan to its IBC and
360 the department for approval and shall update the plan annually, if
361 necessary. The training plan shall ensure that all laboratory staff and
362 researchers, including the principal investigator for each facility, are
363 trained adequately and that the principal investigator participates in
364 the creation and implementation of the training plan. No individual
365 other than a local, state or federal government representative
366 requiring access for regulatory compliance or investigative purposes
367 may enter a high containment biological research laboratory located
368 within a facility without first completing the facility's training plan.

369 (9) Require each facility with a high containment biological
370 research laboratory to have and implement a waste management and
371 decontamination plan approved by the department.

372 (e) A facility with a high containment biological research labora-
373 tory shall develop an emergency response plan, in conjunction with
374 local and state officials, that addresses security threats and releases
375 and spread of pathogenic biological agents and toxins. The emer-
376 gency response plan shall comply with local, state or federal plans
377 already in existence. The plan must address such events as severe
378 weather (such as hurricanes and floods), earthquakes, power out-
379 ages, terrorism, and other natural, accidental, or intended disasters or
380 emergencies. The emergency response plan shall at a minimum
381 address the following:—

382 (1) The hazards associated with the use of the select agents and
383 toxins and special procedures needed to address the hazards of spe-
384 cific select agents and toxins.

385 (2) Personnel roles, lines of authority, training, and communica-
386 tion.

387 (3) Emergency assessment and prevention.

388 (4) Site security and control.

389 (5) Evacuation routes and procedures.

390 (6) Decontamination.

391 (7) Emergency medical treatment and first aid.

392 (8) Emergency alerting and response procedures.

393 (9) Personal protective and emergency equipment.

394 (10) Regularly scheduled preparedness exercises in coordination
395 with local public health and safety officials.

396 (11) Critique of response and follow-up after an incident has
397 occurred.

398 (12) Communication to the public and news media.

399 (f) A facility with a BSL4 laboratory shall coordinate with a hos-
400 pital within a five mile radius of the facility for a medical response
401 to human exposure to a pathogenic biological agent or toxin, and do
402 so in conformity with existing public health guidelines and regula-
403 tions. If there is no hospital medically equipped to coordinate this
404 type of response within a five mile radius of said facility, then the
405 coordination shall be performed at the closest hospital to the facility
406 so equipped. Said coordination shall include, but not be limited to,
407 addressing transportation, isolation, and quarantine issues as appro-
408 priate to the diseases caused by select agents and toxins at the
409 facility. If the closest hospital has created a plan in collaboration
410 with the department under the Bioterrorism Grant Program, the
411 facility is not required to pay for the cost of annual drills.

412 (g) Every facility that has a high containment biological labora-
413 tory shall purchase property and general liability insurance. The
414 insurance shall provide compensation for harm that would be caused
415 to facility workers and the public in the event of a release of a toxin
416 or agent or other hazardous exposure to dangerous pathogens, and
417 from damages caused by a terrorist attack on the facility.

418 (h) No employee, researcher, or student shall be required to con-
419 duct scientific research, experimentation, or study or take other
420 action in a facility with a high containment biological research labo-
421 ratory that violates any provision of this section or has reasonable
422 potential to adversely affect public or worker health, safety, or the
423 environment.

424 (i) A facility with a high containment biological research labora-
425 tory shall not take any retaliatory action against an employee,
426 researcher, or student in the facility because that person discloses or
427 threatens to disclose to a supervisor or a public body an activity,
428 policy or practice that the employee, researcher or student reason-
429 ably believes is in violation of this section or objects to or refuses to
430 participate in any activity, policy or practice that the employee,
431 researcher or student reasonably believes is in violation of this
432 section.

433 (1) The protection against retaliatory action shall not apply to the
434 public disclosure of confidential or proprietary information, trade
435 secrets or other confidential materials unless the employee,
436 researcher or student makes such disclosure directly and exclusively

437 to the office of the attorney general or the department. The depart-
438 ment shall not publicly disclose any such confidential information,
439 but shall submit the information to the Attorney General forthwith.
440 (2) An employee, researcher or student aggrieved by a violation of
441 this subsection may, within two years, file a complaint with the
442 attorney general, who may bring an action in the name of the Com-
443 monwealth against the facility alleged to have violated this section.
444 Provided further, that within ninety days of receiving said complaint,
445 the attorney general shall notify the complainant in writing as to
446 whether he intends to bring an action in the name of the Common-
447 wealth. If the attorney general declines to bring an action based on
448 the complaint filed, the aggrieved employee, researcher or student
449 may, within one year, institute a civil action in the superior court.
450 Any party to said action shall be entitled to claim a jury trial. All
451 remedies available in common law tort actions shall be available to
452 prevailing plaintiffs. These remedies are in addition to any legal or
453 equitable relief provided herein. The court may:—
454 (i) issue temporary restraining orders or preliminary or permanent
455 injunctions to restrain continued violation of this section;
456 (ii) reinstate the employee, researcher or student to the same posi-
457 tion held before the retaliatory action, or to an equivalent position;
458 (iii) reinstate full fringe benefits and seniority rights to the
459 employee, researcher or student;
460 (iv) compensate the employee, researcher or student for three
461 times the lost wages, benefits and other remuneration, and interest
462 thereon; and
463 (v) order payment by the facility of reasonable costs, and attor-
464 neys' fees.
465 (3) In any action brought by an employee, researcher or student
466 under subsection (2), if the court finds said action was without basis
467 in law or in fact, the court may award reasonable attorneys' fees and
468 court costs to the facility. An employee, researcher or student shall
469 not be assessed attorneys' fees if, after exercising reasonable and
470 diligent efforts after filing a suit, the employee, researcher or student
471 moves to dismiss the action against the facility, or files a notice
472 agreeing to a voluntary dismissal, within a reasonable time after
473 determining that the facility would not be found liable for damages.
474 (4) Nothing in this subsection shall be deemed to diminish the
475 rights, privileges or remedies of any employee, researcher or student

476 under any other federal or state law or regulation, or under any col-
477 lective bargaining agreement or employment contract.

478 (5) A facility with a high containment biological research labora-
479 tory shall publicly display notices designed to inform its employees,
480 researchers and students of their protections and obligations under
481 this subsection, and use other appropriate means to keep its
482 employees, researchers or students so informed. Each notice posted
483 pursuant to this subsection shall include the name of the person or
484 persons the facility has designated to receive written notification of a
485 suspected violation of this section.

486 (j) A facility with a high containment biological research labora-
487 tory shall have a security plan developed in coordination with state
488 and local public safety officials. The security plan shall describe the
489 deployment of security guards; the number of guards at each facility;
490 other protective measures, including, coordination of security
491 response with Federal, State, and Local authorities; restricted per-
492 sonnel access to each BSL3 and BSL4 laboratory; perimeter site
493 security, internal site security, and fire protection barriers; and back-
494 ground security clearance for employees and prospective employees.
495 If, at any time, the department of public safety determines that the
496 security plan or implementation of the security plan for a BSL3 or
497 BSL4 facility or laboratory is insufficient to ensure its security, the
498 municipality or department of public safety shall submit to the
499 facility a report that identifies the vulnerability of the facility or lab-
500 oratory, and recommended actions to eliminate the vulnerability.
501 Said recommendations or other remedial actions shall be imple-
502 mented by the facility immediately.

503 (k) To ensure compliance with this section and to protect the
504 public health and safety and the environment, the department shall
505 have the authority to review all documentation relating to the opera-
506 tions of a high containment biological research laboratory and con-
507 duct physical inspections of any such laboratory, and any other part
508 of a facility that supports the laboratory, with or without prior notice;
509 so long as such inspections are conducted at reasonable times and in
510 a manner that maintains the health and safety systems of the labora-
511 tory.

512 (l) A person who willfully or knowingly violates this section or a
513 regulation promulgated pursuant to this section is subject to judi-
514 cially imposed criminal and civil penalties as well as civil

515 administrative penalties. Each day that a violation occurs or con-
516 tinues constitutes a separate violation. A violation may be punished
517 by the administrative imposition of a penalty of not less than \$100
518 and not more than \$25,000 for each day of violation. A violation
519 may be punished by a fine not less than \$100 and not more than
520 \$25,000, or by imprisonment for not more than two years in the
521 house of correction. Punishment imposed under this section does not
522 preclude any other penalty prescribed by law.

523 (m) If a facility or laboratory remains in violation of this section
524 or a regulation promulgated pursuant to this section after written
525 notice from the department without taking reasonable steps to alle-
526 viate the violation, the department shall have the authority to close
527 the facility or laboratory until the violation is remedied. If the
528 department finds that an imminent and substantial threat to worker
529 or public health or safety or the environment exists in a facility or
530 laboratory, it may request the attorney general bring suit or an action
531 for injunctive relief.

532 (n) Each municipality in the Commonwealth shall have the
533 authority to regulate and prohibit high containment biological
534 research laboratories within its jurisdiction. If a municipality has a
535 regulatory program for high containment biological research labora-
536 tories that the department finds is at least as protective of worker and
537 public health and safety and environment as this program, upon
538 request of the municipality the department may certify the municipal
539 program to operate in the place of this program in the municipality.

1 SECTION 2. The Department of Public Health shall adopt regula-
2 tions to implement this act within one year after the effective date of
3 this act.

1 SECTION 3. Section 19(d)(2), concerning whether to approve the
2 siting of a new BSL4 laboratory, shall not apply to any building
3 intended to include a BSL4 laboratory that has a building permit and
4 is under construction as of the effective date of this act.

